| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Merck |
| Recipient: You |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Janssen |
| Recipient: You |
| Company: Roche |
| Recipient: You |
| Company: Astellas Pharma |
| Recipient: You |
| Company: Gilead Sciences |
| Recipient: You |
| Company: Fresenius Kabi |
| Recipient: You |
| Company: CG Oncology |
| Recipient: You |
| Company: Strata Oncology |
| Recipient: You |
| Company: ImmunityBio |
| Recipient: You |
| Company: Asieris Pharmaceuticals |
| Recipient: You |
| Company: Abbvie |
| Recipient: You |
| Company: Bicycle Therapeutics |
| Recipient: You |
| Company: Replimune |
| Recipient: You |
| Company: Daiichi Sankyo |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: QED Therapeutics |
| Recipient: Your Institution |
| Company: Mirati Therapeutics |
| Recipient: Your Institution |
| Company: EMD Serono |
| Recipient: Your Institution |
| Company: G1 Therapeutics |
| Recipient: Your Institution |
| Company: Gilead Sciences |
| Recipient: Your Institution |
| Company: Acrivon Therapeutics |
| Recipient: Your Institution |
| Company: ALX Oncology |
| Recipient: Your Institution |
| Company: Genentech |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|